Jazz Pharmaceuticals plc will be presenting new data for the investigational compound JZP-110 (previously ADX-N05) at the 28th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, May 31 to June 4, 2014 in Minneapolis. The JZP-110 abstract was accepted as a late-breaker oral presentation.
The abstract titled “Efficacy and Safety of Oral ADX-N05 for the Treatment of Excessive Daytime Sleepiness in Adults with Narcolepsy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial” will be presented during the Late-breaking Abstracts oral presentation session on Monday, June 2 from 1:25 pm to 1:40 pm.
Company management will host a live audio webcast following the presentation at 4 pm CDT/10 pm IST to discuss the data presented and provide an overview of JZP-110 and other clinical development programs in narcolepsy and sleep. Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.
